Literature DB >> 32437670

Endothelial cell loss after Descemet's membrane endothelial keratoplasty for Fuchs endothelial dystrophy: DMEK compared to triple-DMEK.

David Shahnazaryan1, Aida Hajjar Sese1, Emma J Hollick2.   

Abstract

PURPOSE: This study compared the outcomes of Descemet's membrane endothelial keratoplasty (DMEK) in pseudophakic patients with the outcomes after DMEK combined with cataract surgery (triple-DMEK) in patients with Fuchs endothelial dystrophy (FED).
DESIGN: Retrospective, single-institution, interventional, consecutive case series.
METHODS: Outcomes of 114 DMEKs in patients with FED and a minimum of 1-year follow-up were reviewed; 34 eyes (29 patients) were pseudophakic and underwent DMEK-only and 80 eyes (56 patients) underwent triple-DMEK. Main outcome measures included endothelial cell loss (ECL), best-corrected visual acuity (BCVA), central corneal thickness (CCT) and complications.
RESULTS: One-month ECL was 25% (±16) and 35% (±15) in DMEK-only and triple-DMEK groups respectively. One-year ECL was 33% (±13) and 41% (±16) in DMEK-only and triple-DMEK groups. There was statistically significantly less ECL after DMEK-only than after triple-DMEK at both 1 month (95% confidence interval [CI], 1.67 to 15.02; P = .016) and 1 year (95% CI, 1.06 to 14.07; P = .034). CCT was significantly lower after DMEK-only than triple-DMEK at 1 month, but not at 1 year. BCVA was excellent and similar in the two groups. There were no cases of graft failure, while graft rejection (8.8% vs 8.75%; P = 0.50) and rebubbling rates (2.9% vs 2.5%; P = 0.44) were similar in the two groups.
CONCLUSIONS: Both DMEK-only and triple-DMEK groups have very low rebubbling rates and good visual outcomes, however combined triple-DMEK procedure resulted in significantly greater loss of endothelial cells compared to DMEK-only surgery at both 1 month and 1 year.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32437670     DOI: 10.1016/j.ajo.2020.05.003

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  "Endothelium-Out" and "Endothelium-In" Descemet Membrane Endothelial Keratoplasty (DMEK) Graft Insertion Techniques: A Systematic Review With Meta-Analysis.

Authors:  Hon Shing Ong; Hla M Htoon; Marcus Ang; Jodhbir S Mehta
Journal:  Front Med (Lausanne)       Date:  2022-06-14

2.  Cataract surgery in patients with Fuchs' dystrophy and corneal decompensation indicated for Descemet's membrane endothelial keratoplasty.

Authors:  Wei-Yi Chou; Yih-Shiuan Kuo; Pei-Yu Lin
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

3.  Descemet's Membrane Endothelial Keratoplasty and Phacoemulsification: Combined versus Sequential Surgery.

Authors:  Ahmed Mahmoud Ragab Mahmoud Hussien; Ahmed Elmassry; Alaa Atef Ghaith; Mohamed Bahgat Badawi Goweida
Journal:  J Curr Ophthalmol       Date:  2021-10-22

4.  Identification of the preoperative and perioperative factors that predict postoperative endothelial cell density after Descemet membrane endothelial keratoplasty: A retrospective cohort study.

Authors:  Dimitri Chaussard; Florian Bloch; Arpiné Ardzivian Elnar; Yinka Zevering; Jean-Charles Vermion; Rémi Moskwa; Jean-Marc Perone
Journal:  PLoS One       Date:  2022-02-24       Impact factor: 3.240

5.  Comparison of triple-DMEK to pseudophakic-DMEK: A cohort study of 95 eyes.

Authors:  Axelle Semler-Collery; Florian Bloch; George Hayek; Christophe Goetz; Jean Marc Perone
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.240

6.  Ability of routinely collected clinical factors to predict good visual results after primary Descemet membrane endothelial keratoplasty: a cohort study.

Authors:  Florian Bloch; Vincent Dinot; Christophe Goetz; Yinka Zevering; Louis Lhuillier; Jean-Marc Perone
Journal:  BMC Ophthalmol       Date:  2022-08-24       Impact factor: 2.086

7.  Changes in Corneal Parameters after DMEK Surgery: A Swept-Source Imaging Analysis at 12-Month Follow-Up Time.

Authors:  Anna Machalińska; Agnieszka Kuligowska; Karolina Kaleta; Monika Kuśmierz-Wojtasik; Krzysztof Safranow
Journal:  J Ophthalmol       Date:  2021-07-21       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.